Magic mushroom compound tested for OCD: early trial shows promise
NCT ID NCT05370911
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This early-stage study is testing whether repeated doses of psilocybin, the active ingredient in magic mushrooms, can reduce symptoms of obsessive-compulsive disorder (OCD). The trial involves 30 adults with severe OCD who have not responded well to standard treatments. Researchers are measuring changes in OCD severity and exploring how psilocybin might work in the brain to ease symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Enact Research Collaborative (40 Temple St, 4th Floor)
New Haven, Connecticut, 06510, United States
-
Yale Program for Psychedelic Research
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.